Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven D Gore

Showing results (71-80 of 215) with videos related to

Pageof 22
Sort By:
Biomedical Chromatography : BMC|April 18, 2022
Validation of a robust and rapid liquid chromatography tandem mass spectrometric method for the quantitative analysis of navitoclaxSusan C Scott, Nicole M Anders, Ping He, et al.
Cancer|August 8, 2013
Lenalidomide performance in the real world: patterns of use and effectiveness in a Medicare population with myelodysplastic syndromesAmer M Zeidan, Steven D Gore, Diane L McNally, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 19, 2010
5-azacytidine as salvage treatment in relapsed myeloid tumors after allogeneic bone marrow transplantationJavier Bolaños-Meade, B Douglas Smith, Steven D Gore, et al.
Haematologica|November 13, 2012
Treatment and outcomes for chronic myelomonocytic leukemia compared to myelodysplastic syndromes in older adultsDan P Zandberg, Ting-Ying Huang, Xuehua Ke, et al.
Journal of Comparative Effectiveness Research|August 15, 2015
Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromesAmer M Zeidan, Franklin Hendrick, Erika Friedmann, et al.
Cancer|March 13, 2016
Disease-related costs of care and survival among Medicare-enrolled patients with myelodysplastic syndromesAmer M Zeidan, Rong Wang, Amy J Davidoff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2005
Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignanciesMichelle A Rudek, Ming Zhao, Ping He, et al.
Journal of Oncology Practice|January 8, 2015
Patient cost sharing and receipt of erythropoiesis-stimulating agents through medicare part DAmy J Davidoff, Franklin B Hendrick, Amer M Zeidan, et al.
Cancer|June 23, 2017
Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantationLucy Hui, Gottfried von Keudell, Rong Wang, et al.
Research Square|June 5, 2025
RNA processing kinase inhibitors and epigenetic inhibitors in combination with oncology drugs or investigational agents in multi-cell type patient-derived tumor cell line spheroidsBeverly A Teicher, Thomas S Dexheimer, Thomas Silvers, et al.
Pageof 22

Showing results (71-80 of 215) with videos related to

Sort By:
Pageof 22
Biomedical Chromatography : BMC|April 18, 2022
Validation of a robust and rapid liquid chromatography tandem mass spectrometric method for the quantitative analysis of navitoclaxSusan C Scott, Nicole M Anders, Ping He, et al.
Cancer|August 8, 2013
Lenalidomide performance in the real world: patterns of use and effectiveness in a Medicare population with myelodysplastic syndromesAmer M Zeidan, Steven D Gore, Diane L McNally, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 19, 2010
5-azacytidine as salvage treatment in relapsed myeloid tumors after allogeneic bone marrow transplantationJavier Bolaños-Meade, B Douglas Smith, Steven D Gore, et al.
Haematologica|November 13, 2012
Treatment and outcomes for chronic myelomonocytic leukemia compared to myelodysplastic syndromes in older adultsDan P Zandberg, Ting-Ying Huang, Xuehua Ke, et al.
Journal of Comparative Effectiveness Research|August 15, 2015
Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromesAmer M Zeidan, Franklin Hendrick, Erika Friedmann, et al.
Cancer|March 13, 2016
Disease-related costs of care and survival among Medicare-enrolled patients with myelodysplastic syndromesAmer M Zeidan, Rong Wang, Amy J Davidoff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2005
Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignanciesMichelle A Rudek, Ming Zhao, Ping He, et al.
Journal of Oncology Practice|January 8, 2015
Patient cost sharing and receipt of erythropoiesis-stimulating agents through medicare part DAmy J Davidoff, Franklin B Hendrick, Amer M Zeidan, et al.
Cancer|June 23, 2017
Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantationLucy Hui, Gottfried von Keudell, Rong Wang, et al.
Research Square|June 5, 2025
RNA processing kinase inhibitors and epigenetic inhibitors in combination with oncology drugs or investigational agents in multi-cell type patient-derived tumor cell line spheroidsBeverly A Teicher, Thomas S Dexheimer, Thomas Silvers, et al.
Pageof 22